Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Public ClinicalTrials.gov record NCT04895436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia
Study identification
- NCT ID
- NCT04895436
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
- Obinutuzumab Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2022
- Primary completion
- Oct 31, 2026
- Completion
- Dec 31, 2028
- Last update posted
- Feb 8, 2026
2022 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center at UC San Diego /ID# 230157 | La Jolla | California | 92093 | Recruiting |
| Winship Cancer Institute of Emory University /ID# 230643 | Atlanta | Georgia | 30322 | Recruiting |
| Des Moines Oncology Research Association /ID# 232606 | Des Moines | Iowa | 50309-1423 | Completed |
| Dana-Farber Cancer Institute /ID# 230061 | Boston | Massachusetts | 02215 | Recruiting |
| Henry Ford Hospital /ID# 230268 | Detroit | Michigan | 48202 | Completed |
| St. Lukes Hospital of Duluth /ID# 250021 | Duluth | Minnesota | 55805 | Recruiting |
| Hattiesburg Clinic /ID# 233443 | Hattiesburg | Mississippi | 39401 | Recruiting |
| Summit Medical Group-Florham Park /ID# 244782 | Florham Park | New Jersey | 07932-1049 | Completed |
| Regional Cancer Care Associates /ID# 244620 | Hackensack | New Jersey | 07601-7015 | Recruiting |
| University of North Carolina /ID# 233313 | Chapel Hill | North Carolina | 27514 | Recruiting |
| Novant Health Presbyterian Medical Center /ID# 230201 | Charlotte | North Carolina | 28204 | Recruiting |
| Novant Health Forsyth Medical Center /ID# 249533 | Winston-Salem | North Carolina | 27103 | Recruiting |
| The Ohio State University /ID# 230439 | Columbus | Ohio | 43210 | Recruiting |
| Pennsylvania Oncology Hematolo /ID# 249637 | Philadelphia | Pennsylvania | 19106 | Recruiting |
| University of Wisconsin-Madiso /ID# 232612 | Madison | Wisconsin | 53705 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04895436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04895436 live on ClinicalTrials.gov.